Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.
暂无分享,去创建一个
T. Matsuda | Y. Ohashi | H. Akaza | M. Igawa | S. Naito | H. Kumon | H. Kanetake | Y. Arai | A. Yamaguchi | M. Usami | A. Soeda